Leaked news from the future.
Tap to receive
The FDA will approve intismeran autogene by December 31, 2027. Moderna and Merck will claim a regulatory win after the Phase 3 INTerpath-001 trial (NCT05933577) that enrolled 1,137 patients with high-risk stage IIB to IV melanoma. Regulators will point to the August 19, 2026 interim analysis that s…